Pharmafile Logo

CanCon

The dark side of direct-to-consumer genetic tests

Direct-to-consumer testing is an affordable way to better understand your DNA, but is this a leap forward in innovation or another layer clouding an already complex market? From anxious patients...

Blue Latitude Health

- PMLiVE

J&J files ‘breakthrough’ bladder cancer drug in US

Needed as most patients don't respond to checkpoint inhibitors

- PMLiVE

AZ nabs US approval for new leukaemia drug Lumoxiti

Adds to firm's growing oncology franchise

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Alnylam gets EU nod for Onpattro amid pricing backlash

However the drug’s price could be lowered in the EU due to direct competition

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

Successful brands tell stories

Creating a strong brand story is the first step in developing a successful pharma brand. Here, Head of Insight Martine Leroy and Jocelyn Coutinho reveal the tools and techniques they...

Blue Latitude Health

- PMLiVE

Nanobiotix signs €40m deal with the EIB

loan to fund innovative nanomedicine platform

- PMLiVE

May’s Brexit plan cautiously welcomed by biopharma sector

The white paper says the UK should adhere to EMA regulations post-Brexit

SWITCHED ONcology Patient Experience Focus Group Full Discussion

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. In...

Havas Lynx

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links